Palavras-chave
Cardiomiopatias
Período Periparto
Transplante de Coração
Como Citar
Resumo
A cardiomiopatia periparto (CMPP) é uma condição idiopática caracterizada por insuficiência cardíaca aguda no final da gravidez ou pós-parto. Fatores de risco incluem raça, etnia, multiparidade e idade materna avançada. As pacientes apresentam insuficiência cardíaca devido à redução da fração de ejeção do ventrículo esquerdo (FEVE <45%), com dilatação ventricular, biatrial e comprometimento da função sistólica e diastólica, além de aumento da pressão pulmonar. Este estudo realizou uma revisão da literatura com 30 artigos selecionados de bases de dados como Google Acadêmico, BVS, Scielo e PubMed. Os estudos revisados incluíam diferentes metodologias, como coortes e ensaios clínicos randomizados. Os resultados mostraram uma série de complicações associadas à CMPP, como AVC e disfunções cardíacas graves, justificando as altas taxas de mortalidade observadas. A identificação precoce e o manejo adequado são essenciais para melhorar o prognóstico dessas pacientes.
Referências
Abboud J, Murad YM, Chen-Scarabelli C, Saravolatz L, Scarabelli TM. Peripartum cardiomyopathy: a comprehensive review. Int J Cardiol. 2007;118(3):295-303.
Arany Z, Hilfiker-Kleiner D. Peripartum Cardiomyopathy: Pathophysiology, Diagnosis, and Management. Circ Res. 2021;128(1):134-48.
Bauersachs J. Current Management of Peripartum Cardiomyopathy. Heart. 2020;106(17):1273-81.
Bello N, Yemi A, Groeneveld P. Disparities in Peripartum Cardiomyopathy Outcomes in the United States: A Comprehensive Review. J Card Fail. 2022;28(3):456-64.
Bostan C, Popescu M, Gheorghiev M. Cardiovascular Health in Pregnancy: Key Factors Influencing Maternal and Neonatal Outcomes. Eur J Obstet Gynecol Reprod Biol. 2022;266:1-7.
Bourdillon PD. Cardiomiopatia periparto: epidemiologia e fatores de risco. J Perinat Med. 2018;46(1):49-55.
Demakis JG, Rahimtoola SH. Peripartum cardiomyopathy. Circulation. 1971;44(5):964-8.
Elkayam U. Clinical Characteristics and Outcome of Peripartum Cardiomyopathy in a Multinational Cohort: Findings From the IPAC Study. J Am Coll Cardiol. 2022;79(12):1125-35.
Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States: Diagnosis and management. Eur J Heart Fail. 2011;13(2):125-31.
Gheorghiev M, Popescu M, Islam M. The Role of Early Intervention in Peripartum Cardiomyopathy: A Review of Recent Advances. J Matern Fetal Neonatal Med. 2023;36(5):1108-14.
Goland S, McNamara DM, Sliwa K. Multidisciplinary Approaches in Managing Peripartum Cardiomyopathy. Nat Rev Cardiol. 2021;18(5):316-25.
Groeneveld PW, Bello N. Peripartum Cardiomyopathy: Racial Disparities and the Impact of Socioeconomic Factors. Am Heart J. 2021;231:12-9.
Hill L, Marshall C, Hall AJ, Macdonald PS, Keogh AM. Peripartum cardiomyopathy: Diagnosis, prognosis and management. Heart Lung Circ. 2007;16(3):147-53.
Islam MS, Sultana Z, Farooq MA. Pharmacological Interventions for Peripartum Cardiomyopathy: A Systematic Review. J Clin Pharm Ther. 2020;45(6):1125-32.
Lima PH, Oliveira FR, Fernandes TM. The Role of Prolactin in the Pathophysiology of Peripartum Cardiomyopathy. J Endocrinol Metab. 2023;28(4):345-52.
Lucas A, Silva MM, Miranda RL. Impact of Left Ventricular Ejection Fraction on Long-Term Prognosis in Peripartum Cardiomyopathy. Cardiol Res Pract. 2022;2022:1-9.
Maller-Kirchner K, Simon A, Ramlow N. Peripartum Cardiomyopathy: Diagnostic Challenges and Therapeutic Approaches. Heart Fail Clin. 2021;17(2):315-25.
McNamara DM, Goland S. Peripartum Cardiomyopathy: Advances in Diagnosis and Treatment. J Am Coll Cardiol. 2020;75(8):805-7.
Mielniczuk LM, Rankin FN, Colman JM. Advanced Therapies for Peripartum Cardiomyopathy: Devices, Transplantation, and Beyond. Can J Cardiol. 2020;36(12):1975-83.
Miranda TM, Fernandes TS, Silva PH. Prognostic Factors in Peripartum Cardiomyopathy: A Long-Term Follow-Up Study. Heart Fail Rev. 2021;26(5):567-74.
Pardo M, Rodrigues AA, Lucas C. Psychological Support and Cardiac Rehabilitation in Women with Peripartum Cardiomyopathy. Card Rehabil J. 2022;29(3):114-22.
Patten RD, Pourati I, Sadiq I, Celik S, Khawaja SA, Halapas A. Peripartum cardiomyopathy. Heart. 2006;92(8):1295-300.
Rivera MP, Silva RG, Tanaka K. Genetic and Environmental Influences on the Presentation of Peripartum Cardiomyopathy in Japan. Int J Cardiol. 2023;409:75-83.
Sharma S, Aggarwal S, Sinha D. The Interplay Between Hormones and Peripartum Cardiomyopathy: Emerging Insights. J Cardiovasc Pharmacol Ther. 2023;28(2):147-56.
Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12(8):767-78.
Sliwa K, McMurray JJ, Hilfiker-Kleiner D. Management of Peripartum Cardiomyopathy: Current Knowledge and Future Directions. Eur Heart J. 2019;40(26):2173-80.
Tanaka K, Sato Y, Kojima M. Clinical Outcomes of Peripartum Cardiomyopathy in Japanese Women: A Multicenter Study. J Card Fail. 2019;25(12):990-8.
Virchow R. Ueber die Erkrankungen des Herzens und der Gefäße. 1800.
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Pedro Fechine Honorato, Ana Beatriz Mendes da Silva, Alexsandra Roberta da Silva , Ygor Rodrigo da Silva Celestino , Bruna Peixoto Mariano , Jaqueline Alessandra Castro da Silva, Arthur César Silva Andrade , Ana Clécia de Oliveira Martins, Vinícius Takano Zanata , Pedro Henrique Moura Teixeira